Nifty
:
16945.05
Sensex
:
57527.10
-131.85 (-0.77%)
-398.18 (-0.69%)
Nifty
Sensex
:
:
16945.05
57527.10
-131.85 (-0.77%)
-398.18 (-0.69%)

Biocon Ltd.

Pharmaceuticals & Drugs - Global

Rating :
40/99

BSE: 532523 | NSE: BIOCON

NSE BSE
198.70
24-Mar-2023
  • Day's Open
  • Day's High
  • Day's Low
  • Previous Close
  • 207.00
  • 207.00
  • 196.65
  • 207.00
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  6907260
  •  13891.21
  •  388.00
  •  191.55

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 23,867.93
  • 61.50
  • 5
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 27,024.43
  • 0.25%
  • 2.47

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 60.64%
  • 1.00%
  • 12.47%
  • FII
  • DII
  • Others
  • 14.42%
  • 8.64%
  • 2.83%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 12.66
  • 14.69
  • 9.11

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 10.72
  • 12.48
  • 3.50

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 2.45
  • 13.05
  • -5.86

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 49.53
  • 61.89
  • 64.34

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 5.09
  • 5.77
  • 5.63

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 22.35
  • 24.82
  • 23.41

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Dec 22
Dec 21
Var%
Sep 22
Sep 21
Var%
Jun 22
Jun 21
Var%
Mar 22
Mar 21
Var%
Net Sales
2,941.10
2,174.20
35.27%
2,319.70
1,840.40
26.04%
2,139.50
1,760.60
21.52%
2,408.80
1,842.10
30.76%
Expenses
2,296.80
1,686.00
36.23%
1,849.00
1,394.60
32.58%
1,740.10
1,371.30
26.89%
1,816.90
1,406.40
29.19%
EBITDA
644.30
488.20
31.97%
470.70
445.80
5.59%
399.40
389.30
2.59%
591.90
435.70
35.85%
EBIDTM
21.91%
22.45%
20.29%
24.22%
18.67%
22.11%
24.57%
23.65%
Other Income
78.60
48.30
62.73%
64.50
104.90
-38.51%
77.90
47.20
65.04%
67.30
205.40
-67.23%
Interest
120.30
14.70
718.37%
30.00
22.50
33.33%
19.90
19.90
0.00%
10.50
33.90
-69.03%
Depreciation
301.10
205.70
46.38%
230.80
201.50
14.54%
217.50
194.80
11.65%
212.20
184.30
15.14%
PBT
30.10
316.10
-90.48%
257.40
256.60
0.31%
239.90
221.80
8.16%
395.50
435.50
-9.18%
Tax
-4.80
49.30
-
147.30
46.30
218.14%
29.50
57.30
-48.52%
58.60
69.40
-15.56%
PAT
34.90
266.80
-86.92%
110.10
210.30
-47.65%
210.40
164.50
27.90%
336.90
366.10
-7.98%
PATM
1.19%
12.27%
4.75%
11.43%
9.83%
9.34%
13.99%
19.87%
EPS
-0.35
1.56
-
0.39
1.15
-66.09%
1.20
0.70
71.43%
1.99
2.11
-5.69%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Net Sales
9,809.10
8,184.00
7,143.10
6,300.50
5,514.40
4,123.40
3,891.10
3,347.40
3,089.80
2,877.30
2,485.30
Net Sales Growth
28.77%
14.57%
13.37%
14.26%
33.73%
5.97%
16.24%
8.34%
7.39%
15.77%
 
Cost Of Goods Sold
3,262.60
2,718.40
2,243.70
1,989.50
1,896.60
1,636.10
1,446.60
1,290.40
1,255.60
1,186.10
1,044.40
Gross Profit
6,546.50
5,465.60
4,899.40
4,311.00
3,617.80
2,487.30
2,444.50
2,057.00
1,834.20
1,691.20
1,440.90
GP Margin
66.74%
66.78%
68.59%
68.42%
65.61%
60.32%
62.82%
61.45%
59.36%
58.78%
57.98%
Total Expenditure
7,702.80
6,691.40
5,841.00
5,043.50
4,390.60
3,294.30
2,911.60
2,584.30
2,394.00
2,190.20
1,946.30
Power & Fuel Cost
-
316.40
270.30
246.10
239.80
189.00
156.40
184.70
176.70
162.40
142.60
% Of Sales
-
3.87%
3.78%
3.91%
4.35%
4.58%
4.02%
5.52%
5.72%
5.64%
5.74%
Employee Cost
-
1,880.10
1,741.00
1,458.80
1,165.30
931.10
747.00
610.10
533.40
466.30
389.40
% Of Sales
-
22.97%
24.37%
23.15%
21.13%
22.58%
19.20%
18.23%
17.26%
16.21%
15.67%
Manufacturing Exp.
-
1,243.50
1,019.20
864.60
721.20
335.70
391.50
203.70
81.20
62.90
95.20
% Of Sales
-
15.19%
14.27%
13.72%
13.08%
8.14%
10.06%
6.09%
2.63%
2.19%
3.83%
General & Admin Exp.
-
181.50
270.50
182.10
53.00
56.80
21.70
144.60
165.70
131.80
122.20
% Of Sales
-
2.22%
3.79%
2.89%
0.96%
1.38%
0.56%
4.32%
5.36%
4.58%
4.92%
Selling & Distn. Exp.
-
243.80
235.90
266.30
277.50
98.20
107.40
100.80
108.70
118.90
99.60
% Of Sales
-
2.98%
3.30%
4.23%
5.03%
2.38%
2.76%
3.01%
3.52%
4.13%
4.01%
Miscellaneous Exp.
-
107.70
60.40
36.10
37.20
47.40
41.00
50.00
72.70
61.80
99.60
% Of Sales
-
1.32%
0.85%
0.57%
0.67%
1.15%
1.05%
1.49%
2.35%
2.15%
2.13%
EBITDA
2,106.30
1,492.60
1,302.10
1,257.00
1,123.80
829.10
979.50
763.10
695.80
687.10
539.00
EBITDA Margin
21.47%
18.24%
18.23%
19.95%
20.38%
20.11%
25.17%
22.80%
22.52%
23.88%
21.69%
Other Income
288.30
690.30
605.20
507.50
414.30
206.20
157.10
83.90
53.10
55.90
56.70
Interest
180.70
67.60
57.70
64.90
70.90
61.50
26.00
29.30
8.90
1.70
8.10
Depreciation
961.60
814.20
715.10
552.20
447.80
385.10
277.20
248.70
221.00
203.60
179.30
PBT
922.90
1,301.10
1,134.50
1,147.40
1,019.40
588.70
833.40
569.00
519.00
537.70
408.30
Tax
230.60
211.50
221.50
315.10
212.30
156.90
161.60
142.20
95.70
106.90
97.50
Tax Rate
24.99%
17.77%
19.31%
25.94%
17.49%
26.65%
19.39%
19.49%
15.33%
19.88%
15.98%
PAT
692.30
648.40
819.90
777.10
904.40
351.10
595.80
528.70
497.40
413.80
508.90
PAT before Minority Interest
568.00
771.60
925.60
899.80
1,001.70
431.80
671.80
587.40
528.40
430.80
512.70
Minority Interest
-124.30
-123.20
-105.70
-122.70
-97.30
-80.70
-76.00
-58.70
-31.00
-17.00
-3.80
PAT Margin
7.06%
7.92%
11.48%
12.33%
16.40%
8.51%
15.31%
15.79%
16.10%
14.38%
20.48%
PAT Growth
-31.30%
-20.92%
5.51%
-14.08%
157.59%
-41.07%
12.69%
6.29%
20.20%
-18.69%
 
EPS
5.77
5.40
6.83
6.47
7.53
2.92
4.96
4.40
4.14
3.45
4.24

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Shareholder's Funds
8,432.50
7,626.90
6,705.80
6,098.00
5,180.80
4,837.70
4,033.80
3,270.60
3,026.70
2,694.60
Share Capital
600.30
600.00
600.00
300.00
300.00
100.00
100.00
100.00
100.00
100.00
Total Reserves
7,628.10
6,872.80
5,997.00
5,720.80
4,812.30
4,670.20
3,873.00
3,132.70
2,806.20
2,491.80
Non-Current Liabilities
6,802.70
5,496.90
2,684.70
2,122.30
2,006.50
2,304.60
2,421.30
1,377.90
1,262.00
666.30
Secured Loans
2,574.30
1,492.40
1,220.80
1,523.50
1,787.00
2,104.30
2,061.00
758.20
580.40
124.00
Unsecured Loans
1,424.20
1,469.20
1.40
2.10
2.80
3.90
11.40
11.40
25.80
40.00
Long Term Provisions
91.70
106.20
85.80
66.10
49.30
36.00
29.90
15.00
7.80
4.00
Current Liabilities
3,828.00
4,210.10
4,008.00
3,038.50
2,141.30
1,678.30
1,665.70
1,554.70
1,379.60
989.90
Trade Payables
1,608.50
1,513.90
1,325.10
1,198.30
1,005.30
739.70
609.80
429.30
347.20
345.50
Other Current Liabilities
1,031.20
1,840.20
1,784.40
1,374.70
870.10
698.20
527.10
706.20
612.30
313.10
Short Term Borrowings
896.00
594.20
667.60
261.20
130.30
97.20
394.90
261.00
243.50
84.80
Short Term Provisions
292.30
261.80
230.90
204.30
135.60
143.20
133.90
158.20
176.60
246.50
Total Liabilities
20,100.70
18,214.60
14,075.80
11,867.70
9,796.30
9,196.70
8,386.60
6,375.40
5,750.60
4,416.10
Net Block
6,569.00
6,363.90
5,971.10
4,471.00
3,699.50
3,625.10
1,748.30
1,629.90
1,525.20
1,510.30
Gross Block
11,233.00
10,220.90
9,147.40
7,095.00
5,873.80
5,436.10
3,403.60
3,034.20
2,701.70
2,480.90
Accumulated Depreciation
4,664.00
3,857.00
3,176.30
2,624.00
2,174.30
1,811.00
1,655.30
1,404.30
1,176.50
970.60
Non Current Assets
11,718.40
10,614.20
8,750.80
6,979.20
5,647.70
5,149.00
4,415.70
3,812.80
3,111.80
2,176.10
Capital Work in Progress
4,110.40
2,800.20
2,196.00
1,898.90
1,302.80
839.20
2,239.50
1,676.40
1,205.60
312.50
Non Current Investment
370.20
743.20
108.50
182.50
63.80
188.80
26.80
0.00
64.50
64.50
Long Term Loans & Adv.
483.80
436.40
402.00
335.80
437.20
319.70
350.10
336.90
252.00
241.60
Other Non Current Assets
185.00
270.50
73.20
91.00
144.40
176.20
51.00
169.60
64.50
47.20
Current Assets
8,382.30
7,600.40
5,325.00
4,888.50
4,148.60
4,047.70
3,970.90
2,562.60
2,638.80
2,240.00
Current Investments
1,217.70
1,208.70
857.60
829.30
611.40
1,065.00
874.70
230.30
700.40
522.10
Inventories
2,298.20
1,866.60
1,435.90
1,031.60
722.50
635.30
542.40
452.70
376.60
398.40
Sundry Debtors
2,058.20
1,503.30
1,223.70
1,291.80
1,063.90
883.20
714.50
770.50
599.80
509.70
Cash & Bank
1,747.50
2,015.40
998.60
1,057.20
1,322.80
1,044.30
1,538.60
937.50
804.40
672.90
Other Current Assets
1,060.70
713.10
543.60
525.50
428.00
419.90
300.70
171.60
157.60
136.90
Short Term Loans & Adv.
400.50
293.30
265.60
153.10
54.70
24.10
134.70
75.80
81.80
81.40
Net Current Assets
4,554.30
3,390.30
1,317.00
1,850.00
2,007.30
2,369.40
2,305.20
1,007.90
1,259.20
1,250.10
Total Assets
20,100.70
18,214.60
14,075.80
11,867.70
9,796.30
9,196.70
8,386.60
6,375.40
5,750.60
4,416.10

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Cash From Operating Activity
1,176.60
1,159.70
1,283.10
1,154.60
662.10
640.00
370.60
210.70
560.70
471.20
PBT
983.10
1,067.70
870.90
1,002.60
610.00
849.70
751.30
624.10
537.70
610.20
Adjustment
1,245.00
709.60
921.40
472.60
355.70
204.40
42.00
74.00
134.00
147.30
Changes in Working Capital
-789.50
-423.80
-165.10
-29.10
-106.50
-211.10
-176.20
-354.00
37.70
-192.30
Cash after chg. in Working capital
1,438.60
1,353.50
1,627.20
1,446.10
859.20
843.00
617.10
344.10
709.40
565.20
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-262.00
-193.80
-344.10
-291.50
-197.10
-203.00
-246.50
-133.40
-148.70
-94.00
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-1,699.10
-3,624.70
-1,558.90
-713.80
-684.00
-498.50
-1,141.70
-508.70
-938.10
-375.80
Net Fixed Assets
-284.70
-130.90
744.40
-280.60
-177.90
-215.90
-216.90
-57.90
-322.80
-213.80
Net Investments
202.20
-456.90
-890.30
107.80
-310.70
-79.30
-3,688.10
328.50
125.80
38.00
Others
-1,616.60
-3,036.90
-1,413.00
-541.00
-195.40
-203.30
2,763.30
-779.30
-741.10
-200.00
Cash from Financing Activity
242.10
2,564.00
387.60
-241.70
-239.70
-177.50
1,067.60
186.20
426.00
-8.60
Net Cash Inflow / Outflow
-280.40
99.00
111.80
199.10
-261.60
-36.00
296.50
-111.80
48.60
86.80
Opening Cash & Equivalents
897.00
824.70
659.30
449.00
710.20
757.50
457.50
557.00
474.00
369.00
Closing Cash & Equivalent
653.70
897.00
824.70
659.30
449.00
710.20
757.50
462.60
557.00
474.00

Financial Ratios

Consolidated /

Standalone
Description
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Book Value (Rs.)
68.53
62.27
54.97
50.17
42.59
39.74
33.10
26.93
24.21
21.59
ROA
4.03%
5.73%
6.94%
9.25%
4.55%
7.64%
7.96%
8.72%
8.47%
12.28%
ROE
9.83%
13.16%
14.26%
18.00%
8.74%
15.37%
16.31%
17.22%
15.68%
21.50%
ROCE
8.30%
11.30%
14.35%
16.11%
8.92%
12.59%
13.93%
15.30%
15.75%
22.47%
Fixed Asset Turnover
0.76
0.74
0.78
0.85
0.73
0.89
1.05
1.09
1.12
1.11
Receivable days
79.42
69.67
72.86
77.96
86.05
74.35
80.16
80.09
69.48
72.22
Inventory Days
92.87
84.38
71.47
58.05
60.00
54.81
53.71
48.47
48.54
56.01
Payable days
209.62
230.92
81.60
81.98
87.98
78.68
71.28
58.15
55.73
65.24
Cash Conversion Cycle
-37.33
-76.87
62.74
54.04
58.07
50.48
62.59
70.42
62.29
62.99
Total Debt/Equity
0.60
0.58
0.40
0.40
0.44
0.48
0.62
0.35
0.30
0.10
Interest Cover
15.54
20.88
19.72
18.12
10.57
33.05
25.90
71.12
317.29
76.33

Annual Reports:

FY 2022
FY 2021
FY 2020
FY 2019
FY 2018
FY 2017
FY 2016
FY 2015
FY 2014
FY 2013

News Update:


  • Integrated Core Strategies (Asia) buys shares of Biocon for Rs 185 crore
    1st Mar 2023, 15:29 PM

    Integrated Core Strategies (Asia) Pte purchased 80,61,599 shares at an average price of Rs 229.26 each share

    Read More
  • Biocon redeems commercial papers of Rs 2,250 crore
    23rd Feb 2023, 11:19 AM

    The maturity date of the said commercial papers was February 22, 2023

    Read More
  • Biocon raises Rs 1070 crore through NCDs
    22nd Feb 2023, 11:37 AM

    Date of maturity of the said NCDs will be on February 21, 2028

    Read More
  • Biocon recalls 3,665 bottles of Posaconazole Delayed-Release Tablets in US market
    20th Feb 2023, 14:58 PM

    The lot has been manufactured by Biocon Pharma and distributed in the US by Iselin-based Biocon Pharma Inc

    Read More
  • Biocon - Quarterly Results
    14th Feb 2023, 19:18 PM

    Read More
  • Biocon offloads 10% stake in Syngene International
    2nd Feb 2023, 09:59 AM

    The shares were sold at an average price of Rs 560 apiece, taking the transaction value at Rs 2,240 crore

    Read More
  • Biocon’s CSR arm wins IHW Gold Award
    24th Jan 2023, 14:09 PM

    The company has received award for its Oral Cancer Screening Program by IHW Council

    Read More
  • Biocon’s arm recognized as company with great managers at GMA 2022
    22nd Dec 2022, 16:28 PM

    Biocon Biologics is among the Top 50 Companies among 175 participating companies to feature on this prestigious list

    Read More
  • Biocon starts clinical study of Itolizumab for Ulcerative Colitis in India
    15th Dec 2022, 12:07 PM

    The study will cover several tertiary hospitals specialized in handling UC cases

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.